Research and Markets: Abacavir - Pipeline Selector

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/e29254/abacavir_pipelin) has
announced the addition of the "Abacavir - Pipeline Selector" report to their
offering.

Abacavir - Pipeline Developer Indications: In combination with other
antiretroviral agents, indicated for the treatment of HIV-1 infection.
Innovator: GSK (Ziagen, Trizivir, Epzicom, Kivexa)

Eliminate unnecessary risk with the industry benchmark in comprehensive patent
information

Imagine having your own team of pharmaceutical patent experts, at a fraction of
the cost and without the wait. Used by the world's leading generic
pharmaceutical companies and legal teams, Pipeline Developer minimises the risk
of wasted developments or legal action, by providing you with nothing less than
the very best in comprehensive patent information. Searched and analysed by
highly trained, dedicated staff using sophisticated searching techniques,
Pipeline Developer delivers results you can rely on. And that means your staff
can concentrate on how the patent landscape affects your business, rather than
trying to source reliable patent information.

Pipeline Selector: single-drug access to essential competitor, regulatory and
patent expiry information for quick and easy selection of your generics
pipeline.

Pipeline Selector is provided on a per drug basis and is now available in two
access levels; core, covering 7 key countries, and extended, covering 37 ; you
are currently viewing information on the 'extended' version.

Pipeline Selector makes single drug development decisions easy, by quickly
providing you with an accurate snapshot of a single INN, including key patents,
regulatory issues and players. Offering key patent, SPC and data protection
expiry information covering 37 countries, Pipeline Selector gives you exactly
the data you need when you need it, with no commitment to an entire database of
unnecessary information.

Pipeline Selector is an online intelligence tool provided on a per drug basis:

* Includes key patent publications for 37 countries
* Contains SPC protection for every EU state plus patent term extensions in
other countries
* Data exclusivity calculated on a country by country basis
* Summary of dosage forms, strengths, indications and active ingredient forms of
the brand product
* DMF & Paragraph IV filings
* Litigation alerts
* Marketing authorisation holders in selected territories
* Patent risk analysis via graphical display of data from patent filings
* Hyper-linking to crucial patent documents and national registries enabling
data verification

For more information visit
http://www.researchandmarkets.com/research/e29254/abacavir_pipelin

Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009